Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)

Bioanalytical methods are applied at the development and test of drugs as well as at the step of pharmaceutic products issue. Drugs and excipients quality estimation is made by means of precise and reproducible methods. Accuracy and reproducibility of a method is established during validation which is obligatory for medicine registration. The principal task of method validation is experimental evidence of its suitability for the objectives to be achieved. Validation of bioanalytical methods is one of the elements of the whole medicine production validation [1, 2].

The aim of research: to validate a method for determination of specific anti-hemolytic activity of eculizumab developed in LCC “IBC Generium”.

Materials and methods: eculizumab, antibody-sensitized chicken erythrocytes, complement-containing human serum.

Results. We demonstrated the specificity of the method and its correspondence to criteria of accuracy (103.0±1.4)%, robustness (CV – 11.5%), repeatability (CV – (4.9±0.9)%), reproducibility (CV – (3.5±0.4)%), and linearity (k -1.0275; R2 – 0.9975) during validation. The system validity (equipment, materials, analytical operations and analyzed samples) was confirmed for true results obtaining during validation.

Results discussion. Experimental evidence of suitability of the method for eculizumab specific activity assessment was obtained in course of validation. The simplicity of the method allows obtaining accurate results in other laboratories. The developed method can be used not only for specific activity of Soliris determination but also for other pharmaceutical substances and drugs based on antibodies specific to human complement C5.

1. GOST R 52249-2009. Good manufacturing practice for medicinal products (GMP).2010 (In Russian)

2. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. Journal of Pharmaceutical and Biomedical Analysis. 2000, N. 21, рр. 1249-1273.

3. Assay Validation Methods - Definitions and Terms. Available from: http://www.fws.gov/aah/PDF/QI-Terms%20and%20Defs.pdf

4. Hill A., Rother R. P., Arnold L., Kelly R., Cullen M.J., Richards S.J., Hillmen P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica April. 2010, N. 95, рр. 567-573.

5. Johnson R., Hillmen P. Johnson, R. Paroxysmal nocturnal haemoglobinuria: Nature’s gene therapy? J Clin Pathol. 2002, N. 55(3), рр. 145−52.

6. Parker C.1., Omine M., Richards S., Nishimura J., Bessler M., Ware R., Hillmen P., Luzzatto L., Young N., Kinoshita T., Rosse W., Socié G. International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005, N. 106 (12), рр. 3699-709.

7. Hillmen P., Hall C., Marsh J., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., Rother R.P. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria . N Engl J Med. 2004, N. 350 (6). рр. 552−9.

8. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria . Nat Biotech. 2007, N. 25 (11), рр. 1256–64.

9. Scientific discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000791/WC500054212.pdf

10. Guideline on bioanalytical method validation: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.

11. A Step-by-Step Approach to Establishing a Method Validation Program: http://www.ivtnetwork.com/sites/default/files/A%20Step%20by%20Step%20Approach%20to%20Establishing%20a%20Method%20Validation%20Program.pdf

12. Hohensteina A., Hebella M., Zikryb H. Development and validation of a novel cell-based assay for potencydetermination of human parathyroid hormone (PTH). Journal of Pharmaceutical and Biomedical Analysis. 2014, N. 98, рр. 345-350.